Article

Old Arsenal to Combat New Enemy: Repurposing of Commercially Available FDA Approved Drugs Against Main Protease of SARS-CoV2.

2020-10-04

Abstract excerpt

In lack of vaccination and therapeutic drugs, the ongoing COVID-19 pandemic affected millions of people, causing 1,018,957 deaths worldwide (World health organization; 1 st October 2020). The conventional drug design pipeline for effective and safer drug development is a costly and time-intensive affair. It takes around ten years in general from identifying a clinical candidate to get the approvals for actu...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 4a27c5dc-8823-5c7a-9466-3e365f44b81b
DOI: 10.26434/chemrxiv.13032578.v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Old Arsenal to Combat New Enemy: Repurposing of Commercially Available FDA Approved Drugs Against Main Protease of SARS-CoV2.DOI 10.26434/chemrxiv.13032578.v1Read

Identification of novel transmembrane Protease Serine Type 2 drug candidates for COVID-19 using computational studiesSemantic proximity Read

Genetic Algorithm-Based Docking of Potent Inhibitors Against SARS-CoV-2 Main Protease: A Comparison Between Natural Products and Synthetic Drugs.Semantic proximity Read

Drug Repurposing for Candidate SARS-CoV-2 Main Protease Inhibitors by a Novel In Silico MethodSemantic proximity Read

In-Silico Lead Druggable Compounds Identification against SARS COVID-19 Main Protease Target from In-House, Chembridge and Zinc Databases by Structure-Based Virtual Screening, Molecular Docking and Molecular Dynamics SimulationsSemantic proximity Read

Discovering potent inhibitors against the Mpro of the SARS-CoV-2. A Medicinal Chemistry approach.Semantic proximity Read

Interaction of Drug Candidates with Various SARS-CoV‑2 Receptors: An in Silico Study to Combat COVID-19Semantic proximity Read

ABBV-744 and Onalespid as Potential Inhibitors of SARS-CoV-2 main Protease Enzyme: A Promising Therapeutics in COVID-19?Semantic proximity Read

Identification of Potential Antiviral Lead Inhibitors Against Sars-Cov-2 Main Protease: Structure-Guided Virtual Screening, Docking, Adme, and Md Simulation Based ApproachSemantic proximity Read

Structure-Based Virtual Screening to Discover Potential Lead Molecules for the SARS-CoV‑2 Main ProteaseSemantic proximity Read

Drug Repurposing Against SARS-CoV-2 Using E-Pharmacophore Based Virtual Screening and Molecular Docking with Main Protease as the TargetSemantic proximity Read

Identification of repurposing therapeutics toward SARS-CoV-2 main protease by virtual screeningSemantic proximity Read

Identification of promising high-affinity inhibitors of SARS-CoV-2 main protease from African Natural Products Databases by Virtual ScreeningSemantic proximity Read